JBJoshua I. Barzilay

Joshua I. Barzilay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua I. Barzilay has a total of 346 co-authors. Here are the top co-authors by number of shared publications:

  • Kenneth J. Mukamal

    Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, USA

    11 shared publications
  • Petra Buzkova

    Department of Biostatistics, University of Washington , Seattle, WA 98195

    9 shared publications
  • Barry R. Davis

    Coordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, TX, United States of America

    8 shared publications
  • Howard A. Fink

    Geriatric Research Education and Clinical Center, VA Health Care System, Minneapolis, USA

    7 shared publications
  • John A. Robbins

    Department of Medicine, University of California at Davis, Modesto, USA

    7 shared publications
  • Jane A. Cauley

    Department of Epidemiology, Graduate School, School of Public Health, University of Pittsburgh, Pittsburgh, USA

    6 shared publications

Latest Publications

  • Open Access

    Soluble klotho levels and hip fracture risk in the elderly

    by Joshua I. Barzilay, Petra Bůžková, Howard A. Fink, Jane A. Cauley, John A. Robbins, Rachel Elam, Laura Carbone, Kenneth J. Mukamal

    The association between circulating soluble klotho (s-klotho) levels and hip fracture risk is uncertain. We assessed this relationship in 4428 older adults followed for a median of 11.8 years, during which 602 hip fractures occurred. In the overall cohort, s-klotho levels were marginally but not significantly associated with hip fracture risk (hazard ratio (HR) per standard deviation increase, 0.92; 95% CI, 0.83–1.01; p = 0.075). In exploratory analyses, participants in the highest 5% of s-klotho levels (> 1615.2 pg/ml) exhibited a substantially lower risk of hip fracture (adjusted HR, 0.48; 95% CI, 0.27–0.85; p = 0.01), suggesting a threshold effect in which only very high s-klotho concentrations are associated with reduced risk. This finding may help explain inconsistencies in prior studies.


  • Open Access

    Management of glucocorticoid-induced osteoporosis in rheumatic diseases

    by Pritee Shrestha, Sowmya B. Popuri, Colton Hoffer, Anam Qureshi, Joshua Barzilay, Eunice Adu Dapaah, Laura D. Carbone

  • Open Access

    Mortality following atypical femoral fractures in men

    by Colton Hoffer, William Obremskey, Binni Makkar, Brinda Basida, Nitya Shah, Jared D Huling, Zhiping Huo, Emily Budde, Reside Jacob, John T Schousboe, et al.

    Atypical femoral fractures (AFFs) are an uncommon complication of bisphosphonate (BP) treatment for osteoporosis. The purpose of this report was to determine differences in mortality among men treated with BPs who experienced AFFs, hip fractures, or typical subtrochanteric/femoral shaft (ST/FS) fractures. We included men from the Veterans Affairs Corporate Data Warehouse who filled at least one BP prescription over a nearly 20-yr span (October 1, 1999, to December 31, 2022). Typical ST/FS and hip fractures after a first filled prescription for a BP were identified using ICD codes. Radiographic review was conducted for ST/FS fractures to determine which were AFFs using the American Society of Bone and Mineral Research 2014 criterion. Demographic and clinical characteristics and cumulative duration of BP exposure prior to the incident fracture were determined. There were 23 men with an AFF, 4591 with a hip fracture, and 225 with a (non-AFF) ST/FS fracture. At 12-mo post-fracture, 4% of men with an AFF had died, compared with 25% of men with a hip fracture and 15% of men with an ST/FS fracture. Over 5 yrs. of follow-up, mortality following fracture differed among the 3 different fracture groups (χ2 = 6.21, d.f. = 2, p = .045) with death occurring in 7 of 23 (30%) men with an AFF, 2380 of 4591 (52%) men with a hip fracture and 109 of 225 (48%) men with a ST/FS fracture. In Cox proportional hazard models, over 5 yrs, with and without adjustment for covariates, there were no significant differences in mortality following an AFF compared with a hip fracture or an AFF compared with a ST/FS fracture (p > .10 for all). It is possible that mortality is lower following AFF compared with a hip or ST/FS fracture; however, limited sample size among those with AFF may have precluded ascertainment of such a difference.

  • Open Access

    Impact of Renal Disease Markers on Cardiovascular Disease Risk Prediction When Coronary Calcium Score Is Known

    by Joshua Barzilay, Robert Trujillo, Spencer Hansen, Michael Blaha, Matthew Budoff, Robyn L. McClelland

    Background: Markers of renal function have been added to the Predicting Risk of Cardiovascular Disease Events and Systematic Coronary Risk Evaluation cardiovascular risk calculators to enhance risk prediction. Here we examine the role of estimated glomerular filtration (eGFR) and urine albumin creatinine ratio (UACR)—and related dichotomous cut points (eGFR 2 and albuminuria ≥30 mg albumin/gram creatinine)—for prediction of coronary heart disease, cardiovascular disease (CVD) outcomes (CVD mortality, heart failure, stroke, total CVD), and total mortality, using the MESA (Multi‐Ethnic Study of Athersclerosis) calculator, which includes coronary artery calcium scores as a predictor in addition to traditional CVD risk factors. Methods: The study included 6707 participants without clinical CVD with coronary artery calcium scoring. Cox proportional hazards models, adjusted for covariates including coronary artery calcium, were used to gauge the association of UACR, eGFR, albuminuria, and eGFRP 65 years of age, and for all outcomes in participants with diabetes. Conclusions: When coronary artery calcium is known, albuminuria improves heart failure prediction. Albuminuria and UACR each improve total mortality prediction as well. UACR and albuminuria improve prediction for all outcomes in people with diabetes.

  • Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

    by Steven E Kahn, Mark Tripputi, John M Lachin, Ashok Balasubramanyam, Mary Ann Banerji, Joshua Barzilay, Robert M Cohen, W Timothy Garvey, Michaela R Gramzinski, Neda Rasouli, et al.

    OBJECTIVE: To determine the longitudinal effects on α-cell function of four classes of glucose-lowering agents added to metformin in adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a multicenter, randomized study, 5,047 participants ≥30 years of age with type 2 diabetes taking 1,000–2,000 mg metformin daily, HbA1c 6.8%–8.5%, were randomized to receive insulin glargine U100, glimepiride, liraglutide, or sitagliptin. In a subset of 724 participants, baseline and longitudinal measures of α-cell function were assessed as the fasting glucagon concentration and change in glucagon from fasting to 30 min following oral glucose (glucagon index [GGI]). Whether these measures and those of β-cell function (fasting C-peptide and C-peptide index [CPI]) were related to the primary metabolic outcome (HbA1c ≥7.0%) was examined. RESULTS: Baseline fasting glucagon and GGI were not associated with the primary metabolic outcome (2 df; P = 0.55), whereas the β-cell measures were (2 df; P = 0.04). Treatment-associated changes in fasting glucagon, GGI, and fasting C-peptide were not associated with the primary metabolic outcome, while changes in CPI were, in models unadjusted (P < 0.05) or adjusted (P < 0.001) for α-cell function. A 1-SD increase in CPI was associated with a 17% reduction in the risk of the primary metabolic outcome. There were no clear differential effects of the medications on glucagon responses. CONCLUSIONS: There were different patterns of effects of the four glucose-lowering medications on the α-cell, with no relationship of α-cell function with worsening glycemia. Thus, in treating type 2 diabetes, for choice of medication(s) the focus should primarily be on their impact on β-cell function.

  • Open Access

    The Associations of Circulating Sphingolipid Levels with Future Loss of Vibration and Light Pressure Sensation in the Lower Limb

    by Joshua I. Barzilay, Traci M. Bartz, William T. Longstreth, Elsa S. Strotmeyer, Andrew N. Hoofnagle, David Siscovick, Kenneth J. Mukamal, Rozenn N. Lemaitre

    Background: Circulating sphingolipids have been implicated in central nervous system degenerative disorders, but their relationship with peripheral neuropathy remains unclear. Objectives: To evaluate associations between plasma sphingolipid levels and subsequent loss of vibration and light pressure sensation in the lower limbs of older adults. Methods: Plasma concentrations of 11 ceramide (Cer) and sphingomyelin (SM) species were measured in stored samples from 4612 participants in the Cardiovascular Health Study. Vibration sensation was assessed 4–6 years later in 2208 individuals using tuning fork testing, and light pressure sensation was evaluated 11–13 years later in 815 participants using monofilament testing. Sensory impairment was graded on a 3-point scale, with higher scores indicating greater loss. Ordinal logistic regression models examined associations between a doubling of sphingolipid levels and sensory decline, with stratification by diabetes status. Results: In primary models, no sphingolipid species showed significant associations with sensory outcomes. However, after adjusting for inflammatory markers, higher SM-16 levels were linked to increased odds of vibration sensation loss (OR 2.08; 95% CI: 1.11–3.90), while higher SM-24 levels were associated with reduced odds (OR 0.68; 95% CI: 0.46–0.998). Significant interactions with diabetes status were observed for light pressure sensation: SM-14 was associated with increased odds of sensory loss in participants with incident diabetes (OR 5.22; 95% CI: 1.58–17.29), and Cer-18 was associated with increased odds in those with prevalent diabetes (OR 2.38; 95% CI: 1.18–4.78). Conclusions: Elevated levels of specific ceramide and sphingomyelin species may be predictive of future peripheral sensory loss in older adults, with diabetes status influencing these associations.

  • Circulating neurodegenerative brain injury markers and hip fracture and fall hospitalizations: the Cardiovascular Health Study

    by Jane A Cauley, Petra Buzkova, Howard A Fink, Joshua I Barzilay, Rachel E Elam, Oscar L Lopez, Lauren Carlson, John A Robbins, Luc Djousse, Kenneth J Mukamal

    Individuals with dementia have a heightened hip fracture and fall risk but whether markers of brain injury are associated with hip fracture and falls is unknown. We tested the hypothesis that higher circulating brain injury markers were associated with increased risk of hip fracture and fall hospitalizations. Brain injury markers were measured in 2141 participants (mean age 77.9 yr; 60% women). Brain injury markers included neurofilament light chain (NfL), a marker of axonal injury; glial fibrillary acidic protein (GFAP), a marker of astrocytic injury; total Tau, whose many functions include neuron microtubule stabilization; and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), a major protein of neurons. Incident hip fractures and hospitalizations for falls were identified through participant report and confirmed with medical records or medicare claims. Hazard ratios were computed for a doubling exposure (log2 transformed brain injury marker) using multivariable-adjusted Cox models. After a median follow-up of 11 yr, 304 incident hip fractures and 284 incident fall hospitalizations occurred. Doubling of GFAP and NfL were associated with a 22% (p = .048) and 42% (p < .001) higher risk of hip fracture, respectively. Additional adjustment for cognitive function, gait speed, grip strength, inflammatory markers, and depressive symptoms had no effect on results. Models that adjusted for all 4 brain markers showed that only NfL was independent of the other markers. Neurofilament light chain was also associated with a 47% increase risk of hospitalization for falls. There was no association of total Tau or UCH-L1 with hip fracture or falls. GFAP was also unrelated to fall hospitalizations. Neurofilament light chain was independently associated with an incident risk of hip fracture and fall hospitalizations. These results suggest that subclinical degrees of brain injury may contribute to falls and hip fracture. Future research is needed to test whether the association between NfL and hip fracture is independent of falls.

  • Weight change, variability, and trajectories and risk of hip fracture among older adults with dysglycemia: the cardiovascular health study

    by Shohinee Sarma, Petra Bůžková, Rachel E Elam, Howard A Fink, Jane A Cauley, Luc Djoussé, Joshua Barzilay, Kenneth J Mukamal

    Type 2 diabetes mellitus and lower weight are both associated with osteoporotic fractures, but the roles of variability and trajectory are less clear. The associations of these factors among older adults with dysglycemia, who are at highest risk of fracture, with fracture risk and BMD remain uncertain. We followed 775 men and 1080 women from the Cardiovascular Health Study (mean age 77.4 years) with abnormal oral glucose tolerance testing in 1989-1990. We measured their weights yearly through 1994-1995 and derived intra-individual mean weight, weight slope, and weight variability. We also used growth mixture modeling to derive 4 latent BMI trajectories over time. We used Cox proportional hazards models to calculate hazard ratios (HRs) and 95% CI for subsequent hip fracture through 2015 and linear regression models to estimate cross-sectional associations with BMD of the hip. Each 10 kg higher mean weight was associated with a lower risk of subsequent hip fracture overall (HR 0.81; CI, 0.70–0.94) and among women (HR 0.76; CI, 0.64–0.91) and with higher BMD (p <.001). Higher weight variability was directly associated with incident hip fracture among women (HR 1.18; CI, 1.03–1.35). Compared with a stable trajectory, a “progressive overweight” trajectory was associated with lower risk of hip fracture (HR 0.66; CI, 0.44–0.99). An uncommon trajectory of “accelerating obesity” was associated with higher BMD. Among older adults with dysglycemia at high risk for fracture, lower mean weight is associated with higher fracture risk, but variability and trajectory may also contribute. These results highlight the complex effects of weight in older age.


  • The association of microvascular disease and endothelial dysfunction with vertebral trabecular bone mineral density

    by Joshua I. Barzilay, Petra Buzkova, Suzette J. Bielinski, Mary Frances Cotch, Bryan Kestenbaum, Thomas R. Austin, Laura Carbone, Kenneth J. Mukamal, Matthew J. Budoff

    Summary Retinopathy and albuminuria are associated with hip fracture risk. We investigated whether these disorders and endothelial dysfunction (which underlies microvascular diseases) were associated with low trabecular bone density. No significant associations were found, suggesting that microvascular diseases are not related to fracture risk through low trabecular bone density. Purpose Microvascular diseases of the eye, kidney, and brain are associated with endothelial dysfunction and increased hip fracture risk. To explore the basis for higher hip fracture risk, we comprehensively examined whether markers of microvascular disease and/or endothelial dysfunction are related to trabecular bone mineral density (BMD), a proximate risk factor for osteoporotic fractures. Methods Among 6814 participants in the Multi-Ethnic Study of Atherosclerosis study (MESA), we derived thoracic vertebral trabecular BMD from computed tomography of the chest and measured urine albumin to creatinine ratios (UACR), retinal arteriolar and venular widths, flow mediated dilation (FMD) of the brachial artery after 5 min of ischemia; and levels of five soluble endothelial adhesion markers (ICAM-1, VCAM-1, L-selectin, P-selectin, and E-selectin). Linear regression models were used to examine the association of trabecular BMD with markers of microvascular disease and with markers of endothelial dysfunction. Results We observed no significant associations of UACR, retinal arteriolar or venular widths, or FMD with BMD. We also observed no statistically significant association of spine trabecular BMD with levels of endothelial adhesion markers. Men and women had largely similar results. Conclusion We conclude that there is little evidence to connect thoracic spine trabecular BMD to microvascular disorders or to endothelial dysfunction among multi-ethnic middle-aged and older adults. Other factors beyond trabecular BMD (e.g., bone quality or predisposition to falling) may be responsible for the associations of microvascular disease with osteoporotic fractures.